Lyvanta

Lyvanta (UP-085) is a first-in-class preclinical therapeutic developed by U-Ploid Biotechnologies, a UK-based biotechnology company. It is specifically designed to reduce meiotic aneuploidy—chromosomal abnormalities that occur during egg development—which is a primary cause of IVF failure and miscarriage, particularly in women of advanced maternal age. The drug works by stabilizing chromosomal assembly and ensuring the faithful segregation of maternal chromatids during meiosis in oocytes (egg cells). By addressing the root cause of age-related female infertility at the cellular level, Lyvanta aims to improve egg quality during IVF procedures, potentially increasing success rates and reducing the number of cycles required. Preclinical data presented at the American Society for Reproductive Medicine (ASRM) demonstrated an 84.3% reduction in chromosomal separation errors in aged mouse eggs.

Brand names

Lyvanta